Equities Analysts Set Expectations for ProPhase Labs, Inc.’s Q1 2025 Earnings (NASDAQ:PRPH)

ProPhase Labs, Inc. (NASDAQ:PRPH) – Investment analysts at Diamond Equity issued their Q1 2025 earnings per share (EPS) estimates for ProPhase Labs in a report issued on Monday, April 22nd. Diamond Equity analyst H. Diamond forecasts that the company will post earnings per share of $0.10 for the quarter. The consensus estimate for ProPhase Labs’ current full-year earnings is ($0.88) per share. Diamond Equity also issued estimates for ProPhase Labs’ Q2 2025 earnings at $0.12 EPS, Q3 2025 earnings at $0.12 EPS and Q4 2025 earnings at $0.14 EPS.

ProPhase Labs (NASDAQ:PRPH) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.51) earnings per share for the quarter. The firm had revenue of $3.50 million for the quarter, compared to analyst estimates of $10.71 million. ProPhase Labs had a negative return on equity of 29.83% and a negative net margin of 37.81%.

Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of ProPhase Labs in a research report on Wednesday, February 21st.

ProPhase Labs Stock Performance

PRPH opened at $5.16 on Wednesday. The company has a current ratio of 2.28, a quick ratio of 2.10 and a debt-to-equity ratio of 0.29. The firm’s fifty day moving average price is $5.53 and its two-hundred day moving average price is $5.00. ProPhase Labs has a fifty-two week low of $4.05 and a fifty-two week high of $9.94.

Institutional Trading of ProPhase Labs

Several institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC lifted its holdings in shares of ProPhase Labs by 50.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 15,010 shares of the company’s stock valued at $68,000 after acquiring an additional 5,026 shares during the period. SVB Wealth LLC acquired a new position in ProPhase Labs in the third quarter valued at about $208,000. Finally, HighTower Advisors LLC bought a new stake in ProPhase Labs during the third quarter worth about $756,000. Institutional investors and hedge funds own 9.45% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.